- Details
- Hits: 257
Cannabis, cocaine and amphetamines all raise the risk of stroke significantly. That is the central finding of the largest study ever conducted on recreational drugs and stroke risk, drawing on data from more than 100 million people. Researchers at the University of Cambridge published their findings in the International Journal of Stroke in March 2026. The study concludes that these substances do not merely correlate with stroke. They appear to cause it.
The Statistics on Drug Use and Stroke Risk
The study found cocaine use raises stroke risk by 96%. Amphetamines raise it by 122%. Cannabis, often seen as the softer option, still increases the risk by 37%. Researchers found no significant link between opioid use and stroke.
Among adults under 55, the numbers become even more striking. Amphetamine use raises stroke risk by 174% in this age group. That is nearly three times the average person’s risk. Cocaine use in younger adults still carries a 97% elevated risk. Cannabis raises it by 14% in the same group.
Stroke is the third leading cause of death and disability combined worldwide. Most people associate it with older age, high blood pressure or poor diet. This research now adds drug use and stroke to that list of major, modifiable risk factors.
In England and Wales, around 2.9 million adults aged 16 to 59 reported using a recreational drug in 2024. That represents 8.8% of that age group. In the United States, more than half of all people over the age of 12 report having used cocaine, cannabis or opiates at least once.
Recreational Drugs and Stroke Risk: Moving Beyond Correlation
Earlier studies could show a connection between drug use and stroke. But they could not confirm the drugs were the actual cause. Other lifestyle factors among users clouded the picture.
The Cambridge team used a method called Mendelian randomisation to dig deeper. This technique looks at naturally occurring genetic variants linked to drug use and to stroke. It tests whether a true causal relationship exists between the two. The results pointed clearly toward cause, not just correlation.
Cocaine use disorders showed a strong connection to brain haemorrhage and cardioembolic stroke. In cardioembolic stroke, a blood clot forms in the heart and travels to the brain, cutting off blood flow. Cannabis use disorders linked most strongly to large artery stroke.
Dr Megan Ritson from the Stroke Research Group at the University of Cambridge said the research “provides compelling evidence that drugs like cocaine, amphetamines, and cannabis are causal risk factors for stroke.”
Dr Eric Harshfield, an Alzheimer’s Society Research Fellow at the Department of Clinical Neurosciences, was equally direct. He stated that the analysis shows it is the drugs themselves driving the elevated risk, not simply the broader lifestyle of those who use them.
How Recreational Drugs Damage the Brain
The body reacts to these substances in several ways that are known to trigger stroke. Blood pressure spikes sharply and suddenly. Blood vessels go into spasm and constrict. Heart rhythm becomes disrupted. Cannabis use promotes increased blood clotting. Amphetamines can cause inflammation of blood vessel walls.
Each of these reactions is a recognised pathway to stroke. They can lead to ischaemic strokes, which blood clots cause, and to haemorrhagic strokes, which involve bleeding in the brain. The danger does not require years of heavy use. These effects can strike acutely, even in otherwise healthy adults.
What the Research Means for Public Health
Drug use and stroke share a relationship that public health policy can no longer ignore. Dr Harshfield emphasised that reducing substance use would carry a meaningful benefit beyond addiction itself: a measurable reduction in stroke cases.
The research received funding from the British Heart Foundation, with additional support from the National Institute for Health and Care Research Cambridge Biomedical Research Centre.
The evidence now speaks plainly. For more than 100 million reasons, recreational drugs and stroke risk belong in the same sentence.
Source: WRD-News
- Details
- Hits: 843
What’s up your Butt?? Apparently, it’s…Rectal drug use (“boofing”, “plugging” or “booty bumping” if you like?!?) is sold as a clever hack for a faster high, but it’s basically playing Russian roulette with some of the thinnest, most vulnerable tissue in your body. It can feel cleaner or “safer than injecting”, yet the mix of high‑dose drugs, fragile rectal lining and zero margin for error is exactly how people end up in, A&E’s, Eds, ICUs – or not waking up at all.
What “boofing” actually does
When you put drugs into your anus (No, not the planet you may be trying to reach virtually!) they absorb through a dense network of blood vessels and can hit your bloodstream fast, often more directly than if you’d swallowed them. But by ‘by-passing’ the digestive filters like mouth, stomach and liver, you may speed up your potential hi-hit (mainly the mouth, which alcoholics might do to negate the ‘booze breath’) yet that short-cut creates a new set of serious issues, not least being that the dose that seemed fine by mouth can be way too much rectally.
Butt Poison of Choice?
- Stimulants (cocaine, meth, “bath salts”) for a faster, harder rush.
- MDMA at festivals/parties to “make it kick in quicker”.
- Opioids (including strong synthetics) to chase euphoria without injecting.
- Alcohol or GHB/GHB‑like drugs, sometimes mixed with lube.
On the surface it can look controlled – measured dose, a clean ‘syringe barrel’, some lube – but the pharmacology underneath is absolutely not controlled. The same amount can hit you much harder than you expect, and you can’t expel it – you know “vomit it up” once it’s in – that option is gone and ipecac or stomach pumping is of no value in triage.
Why the risk of overdose explodes
Rectal use is often framed as “harm‑reduction compared with injecting”, but overdose risk usually goes up, not down. (Yet just one more example of why ‘harm reduction’ isn’t!)
Key reasons:
- Rapid absorption, tiny safety margin: The drug crosses a thin membrane and blood levels can spike quickly, faster than your brain has time to say “this is too much.”
- Oral doses don’t translate: People copy their usual pill/line dose and push it rectally; what was mild by mouth can become overwhelming via the rectum.
- Redosing trap: If the high feels “slow”, there’s a strong temptation to add more, only for both doses to kick hard together 10–20 minutes later.
With stimulants like meth or cocaine, that spike can mean arrhythmia, heart attack, stroke, seizure and extreme agitation or psychosis. With opioids, it means respiratory depression: simply not breathing deeply enough to stay alive. With alcohol or GHB, you’ve removed vomiting as an emergency safety valve, so you can slide straight from “buzzed” to unconscious, not breathing and needing resuscitation.
What it does to your body, specifically the Butt Hole
The rectum isn’t designed to be a loading dock for powders, crushed pills, crystals or concentrated alcohol (or any foreign object for that matter!) It’s thin, delicate and packed with blood vessels.
Regular or heavy rectal use can cause:
- Tears and bleeding: Small fissures from rough tips, un-dissolved particles, or just repeated irritation, which can be brutally painful and bleed.
- Ulcers, infections, abscesses: Local tissue damage becomes an opening for bacteria, leading to deep infections or pus‑filled pockets that sometimes need surgery.
- Serious structural damage: Repeated trauma can contribute to long‑term problems like incontinence or even rectal prolapse.
Because the lining is thin and highly vascular, it’s also an efficient doorway for blood‑borne infections, including HIV and hepatitis C, especially if equipment is shared or there’s any bleeding
If rectal use intersects with anal sex – before or after – you stack the risks: microscopic injuries from one activity make it easier for infections to cross during the other.
Mental health and the “how did I get here?” moment
By the time someone is boofing, they’re often not at the beginning of their spiralling dysfunctional relationship with drugs. It can signal an escalation: chasing faster, stronger effects as tolerance builds or other routes become harder or feel too embarrassing.
Rectal use doesn’t just affect your body:
- It can amplify anxiety, paranoia and mood swings, particularly with stimulants.
- It can feed into a pattern of secretive, compulsive use – hiding paraphernalia, using alone, and pushing past your own internal “this feels too far” line.
If you’ve ever had a clear, sober moment of “I can’t believe I’m doing this” around drugs and your body, that’s a signal worth listening to. We would posit that even if you don’t get that internal psycho-social alarm, the fact that you’re reading this should become that alarm… yes, you heard right, we used the word should, because it has been stolen from the protective lexicon and it needs to be put back in for your safety and well-being.
When Stupid People Don’t Want to Stop Dumb Acts?
Abstinence is always the safest option, but concerningly harm‑reduction exists precisely because people (for a number of reasons, mostly hedonic idiocy) use drugs in the real world and not in ideal conditions – Durr, ‘partying without purpose’. One damage management public health response is to emphasise reducing preventable harm but still warning people about dumb acts. Are you listening?
If someone chooses to boof despite the risks, potentially (not guaranteed) lower‑risk practices may include things like:
- Avoiding alcohol or GHB rectally entirely (the risk–reward ratio is terrible) There’s that abstinence option!
- Never guessing doses – especially with powders of unknown strength – and not matching oral doses one‑for‑one rectally. When in doubt – don’t! Hey, there’s the abstinence option, again!
- Using clean, dedicated equipment, not sharing, and not using makeshift objects that can scratch or tear.
- Leaving long gaps between doses to see the full effect before even thinking about more. Oooh! Interim abstinence at play – just keep the gap longer and longer.
- Getting regular STI and blood‑borne virus checks and using condoms/PrEP/PEP where relevant.
These strategies do not make boofing “safe” by any stretch; they just reduce some of the more predictable ways it goes very wrong.
When to seek help – immediately
Call emergency services or go to A& E or E.D if, after rectal use, anyone has:
- Trouble staying awake, very slow or strange breathing, blue lips or fingertips.
- Chest pain, palpitations, severe headache, collapse, seizure or extreme agitation/confusion.
- Severe rectal pain, heavy bleeding, fever, or a painful swelling near the anus.
You don’t have to tell staff every detail to get life‑saving care but being honest about the route and substance can help them treat you faster and more effectively.
If some part of you is already uncomfortable with how far your use has gone – or you’re supporting someone else who’s there – that discomfort is actually a healthy signal. It’s a good moment to reach out to a trusted health professional, local alcohol and other drug service, or a confidential helpline to talk through options before the next line, pill or plug pushes you past the point you can come back from.
(Source: Dalgarno Institute)
- Details
- Hits: 391
The psychedelic therapy movement has been sold to the public as a grassroots revolution driven by compassion for suffering veterans and breakthrough science. The reality is far more sinister. A coordinated campaign by Silicon Valley billionaires has hijacked the psychedelic industry, weaponising vulnerable populations whilst suppressing safety concerns that should have halted their plans years ago.
These psychedelic therapy safety concerns extend far beyond isolated incidents—they reveal systematic failures in oversight and accountability that threaten to replicate the opioid crisis under the guise of healing.
The Architect of Capture
The Psychedelic Science Funders Collaborative (PSFC) represents everything dangerous about concentrated wealth meeting unregulated pharmaceutical development. Founded in 2017, this shadowy network of approximately 200 high-net-worth individuals—including SpaceX board members, tech founders, and hedge fund managers—has systematically captured the psychedelic ecosystem. Their wealth exceeds the GDP of small countries, yet their accountability to public health standards remains virtually non-existent.
PSFC member Genevieve Jurvetson acknowledged the disproportionate power wielded by this tiny elite: “This field has been carried by like 20 families, and the leverage that they’ve had with [a] million, you know, tens of millions of dollars—hundreds of millions at this point is really quite extraordinary.”
Extraordinary indeed. Extraordinary in its concentration of control. Extraordinary in its disregard for scientific integrity. Extraordinary in its willingness to experiment on traumatised populations. (for complete expose, WRD News)
- Details
- Hits: 477
The Psychedelic Syndicate: How Silicon Valley Used Veterans to Hijack the Psychedelic Industry
Excerpt from Executive Summary
This report provides an in-depth examination of how a strategic, well-funded campaign operated to influence public perception at the expense of public health.
Psymposia has spent over a year investigating the financial and political forces shaping the psychedelic industry. Through analysis of hundreds of internal documents — including unedited emails, transcripts, presentations, and other primary materials spanning nearly a decade — this report describes the rise of the Psychedelic Science Funders Collaborative (PSFC) and its extensive influence across the field.
The prevailing media narrative has characterized the psychedelic movement as an organic coalition of grassroots activists motivated by psychedelics’ therapeutic potential. Our analysis reveals PSFC's coordinated efforts to circumvent federal regulatory structures and manipulate state-level policy development, transforming a community-led movement into a vehicle for centralized corporate influence.
Following the FDA’s 2024 rejection of MDMA-assisted therapy, PSFC-funded organizations targeted critics and whistleblowers in collaboration with the Psychedelic Communications Hub (now incorporated into the Psychedelic Safety Institute). Organizations involved in this campaign included the Multidisciplinary Association for Psychedelic Studies (MAPS), Lykos Therapeutics, and veterans groups Heroic Hearts Project and Healing Breakthrough.
Having failed to subvert the FDA regulatory process, these groups are now appealing to the Trump administration to accelerate approval based on data from clinical trials characterized by serious scientific failures. Disregarding public safety concerns in their rush to bring an experimental therapy to market, PSFC responded to the FDA's rejection by intensifying strategies that would amount to regulatory capture.
- Details
- Hits: 617
Yet more damaging evidence has emerged against psychedelic treatment, with a comprehensive meta-analysis from UCLA, Imperial College London, and UCSF revealing that magic mushrooms and other substances perform no better than traditional antidepressants.
The findings deliver another significant blow to industry advocates promoting the “psychedelics are medicine” narrative, exposing fundamental flaws in psychedelic therapy that have driven premature enthusiasm for these powerful substances.
Critical Flaws Exposed in Psychedelic Treatment
The study addresses a basic problem plaguing psychedelic therapy: researchers cannot properly “blind” participants because the obvious psychoactive effects make it clear what substance they’re receiving. This “unblinding” significantly affects statistical results and study reliability.
Recognising this endemic issue in psychedelic treatment, the authors compared results with “open-label” antidepressant trials where participants knew they were receiving specific medications.
Substantial Sample Sizes Reveal Troubling Results
The researchers examined eight psychedelic therapy studies involving nearly 550 participants alongside 16 antidepressant trials covering almost 9,800 participants. These substantial sample sizes make the results particularly concerning for advocates.
According to the pre-print: “Contrary to prior hypothesis, PAT was no more effective than open-label traditional antidepressant treatment… PAT’s lack of superiority compared to traditional antidepressants under equal-unblinding conditions highlights the influence of blinding integrity and presents a sobering viewpoint on the treatment’s potential.”
Industry Claims Undermined
This result fundamentally undermines promotional claims made by what the original researchers termed “shroom salesmen.” The evidence advocates previously cited was already problematic, plagued by small sample sizes, conflicts of interest, and methodological issues.
The new analysis suggests that apparent efficacy in psychedelic treatment stems from “unblinding” effects rather than genuine therapeutic benefits from the substances themselves.
Urgent Need to Halt Premature Implementation
These findings provide yet another compelling reason to halt efforts to fast-track these dangerous, powerful, and potentially life-altering substances into medical treatments.
The concerning results from this rigorous psychedelic therapy analysis highlight the risks of rushing experimental treatments into clinical practice without proper scientific validation.
Given the mounting evidence against efficacy claims, authorities must exercise extreme caution before approving psychedelic treatment applications for mainstream medical use, particularly given the vulnerable nature of patients seeking depression treatment.(Source: WRD News)
- Psilocybin Teen Risks: Hidden Dangers of Magic Mushrooms
- Drug-Related STI Prevention: Research Reveals Critical Prevention Gaps
- Australia Seizes 10 Million Vapes: World-Leading Crackdown Shows Dramatic Results in Youth Prevention
- Social Media Teen Substance Use Crisis: How Online Platforms Are Driving Youth Vaping and Cannabis Epidemic